Why the study?
Does a single oral dose of BAY 63-2521 affect safety, pharmacokinetics, and pharmacodynamics compared to placebo in healthy male volunteers?
Does a single oral dose of BAY 63-2521 affect safety, pharmacokinetics, and pharmacodynamics compared to placebo in healthy male volunteers?
BAY 63-2521 is well-tolerated, exhibits dose-proportional pharmacokinetics, and demonstrates dose-dependent vasodilatory effects in healthy male volunteers, supporting its development for pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Supports development for pulmonary hypertension; extends pharmacodynamic data from healthy volunteers to patient trials.
Frey et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: